By Fineline Cube Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which includes mainland China, Hong Kong, and Taiwan. Dr. Pavol Dobrocky will be succeeded by Mohammed Tawil as the president and chief executive officer (CEO).
Mohammed Tawil’s Background and Experience
Mohammed Tawil currently serves as the president, CEO, and head of the Human Medicines business unit for BI’s IMETA region, which encompasses India, Middle East, Turkey, and Africa. Tawil joined BI in 1995 as a medical representative in the Jordan office and has since held a series of significant positions across the Near East, Middle East, and North Africa. In 2017, he moved to the company headquarters to serve as the regional business manager for human resources and the drug division, focusing on markets in China, Mexico, Brazil, and South America.
Dr. Pavol Dobrocky’s Tenure
Dr. Pavol Dobrocky arrived in China in 2020 and has since served as the general manager of BI’s Greater China Human Medicines sector. He was appointed as the Greater China president and CEO earlier this year, contributing significantly to the company’s growth and strategic initiatives in the region.-Fineline Info & Tech